CO2022002616A2 - Composiciones de trofinetida - Google Patents

Composiciones de trofinetida

Info

Publication number
CO2022002616A2
CO2022002616A2 CONC2022/0002616A CO2022002616A CO2022002616A2 CO 2022002616 A2 CO2022002616 A2 CO 2022002616A2 CO 2022002616 A CO2022002616 A CO 2022002616A CO 2022002616 A2 CO2022002616 A2 CO 2022002616A2
Authority
CO
Colombia
Prior art keywords
compositions
compounds
trofinetide
products
methods
Prior art date
Application number
CONC2022/0002616A
Other languages
English (en)
Inventor
Clive Blower
Mathew Peterson
James Murray Shaw
James Anthony Bonnar
Etienne David Frank Philippe Moniotte
Martin Bernard Catherine Bousmanne
Cecilia Betti
Karel Willy Luc Decroos
Mimoun Ayoub
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of CO2022002616A2 publication Critical patent/CO2022002616A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18—Carbon
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta descripción describe compuestos de Fórmula (I), estereoisómeros, compuestos secundarios de estos, composiciones farmacéuticas y métodos para elaborar tales compuestos, que utilizan reactivos de sililación y que producen composiciones y productos preparados utilizando tales métodos. Más particularmente, esta divulgación describe la elaboración de trofinetida y productos secundarios, composiciones y productos que contienen tales compuestos, para usos farmacéuticos con el fin de tratar trastornos neurodegenerativos o del neurodesarrollo.
CONC2022/0002616A 2019-08-05 2022-03-04 Composiciones de trofinetida CO2022002616A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882998P 2019-08-05 2019-08-05
PCT/US2020/044733 WO2021026066A1 (en) 2019-08-05 2020-08-03 Compositions of trofinetide

Publications (1)

Publication Number Publication Date
CO2022002616A2 true CO2022002616A2 (es) 2022-06-10

Family

ID=74502416

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0002616A CO2022002616A2 (es) 2019-08-05 2022-03-04 Composiciones de trofinetida

Country Status (14)

Country Link
US (3) US11370755B2 (es)
EP (1) EP4009962A4 (es)
JP (1) JP2022543391A (es)
KR (1) KR20220059479A (es)
CN (1) CN114667136A (es)
AU (1) AU2020324396A1 (es)
BR (1) BR112022002229A2 (es)
CA (1) CA3149633A1 (es)
CL (1) CL2022000301A1 (es)
CO (1) CO2022002616A2 (es)
IL (1) IL290324A (es)
JO (1) JOP20220027A1 (es)
MX (1) MX2022001505A (es)
WO (1) WO2021026066A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114667136A (zh) 2019-08-05 2022-06-24 诺仁制药有限公司 Trofinetide的组合物
BR112023026559A2 (pt) 2021-07-12 2024-03-05 Acadia Pharm Inc Formas cristalinas de trofinetida

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573765B1 (fr) * 1984-11-23 1988-06-10 Solvay Procede pour la synthese de peptides
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
WO2006127702A2 (en) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
JP2004536069A (ja) 2001-05-24 2004-12-02 ニューロンズ・リミテッド Ｇｐｅ類縁体及びペプチドミメティック
ES2487493T3 (es) * 2006-03-14 2014-08-21 Neuren Pharmaceuticals Limited Formulaciones orales de glicil-2-metilprolil-glutamato
EP2060580A1 (en) * 2007-11-19 2009-05-20 SOLVAY (Société Anonyme) Process for the manufacture of persilylated peptides
PL2667715T3 (pl) 2011-01-27 2018-02-28 Neuren Pharmaceuticals Limited Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego
CN114667136A (zh) * 2019-08-05 2022-06-24 诺仁制药有限公司 Trofinetide的组合物

Also Published As

Publication number Publication date
US20240109841A1 (en) 2024-04-04
JP2022543391A (ja) 2022-10-12
US11370755B2 (en) 2022-06-28
US20220055987A1 (en) 2022-02-24
EP4009962A1 (en) 2022-06-15
CL2022000301A1 (es) 2022-09-20
MX2022001505A (es) 2022-03-11
JOP20220027A1 (ar) 2023-01-30
BR112022002229A2 (pt) 2022-04-19
EP4009962A4 (en) 2023-08-09
US20220324799A1 (en) 2022-10-13
CA3149633A1 (en) 2021-02-11
CN114667136A (zh) 2022-06-24
WO2021026066A1 (en) 2021-02-11
KR20220059479A (ko) 2022-05-10
US11866406B2 (en) 2024-01-09
IL290324A (en) 2022-04-01
AU2020324396A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CO2018011550A2 (es) Compuestos de pirrolotriazina como inhibidores de tam
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
CL2021001171A1 (es) Compuestos de anillo fusionado.
CO2022002616A2 (es) Composiciones de trofinetida
BR112018076443A2 (pt) formas cristalinas de um composto de triazolopirimidina
UY36530A (es) Métodos para purificar cannabinoides, composiciones y kits de estos
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CR20140411A (es) Compuestos de indol e indazol que activan la ampk
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
BR112018014015A2 (pt) derivados de tioidantoína substituídos como antagonistas do receptor de androgênio
BR112017024243A2 (pt) Sal de (s)-csa de s-cetamina, sal de (r)-csa de s- cetamina e processos para a preparação de s- cetamina
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CO2021006672A2 (es) Moduladores de nlrp3
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2019002438A (es) Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.
CL2020002275A1 (es) Compuestos diólicos de aminopirazina como inhibidores de pi3k-y.
BR112021018456A2 (pt) Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
CL2020000085A1 (es) Moduladores de nlrp3.
CL2018003377A1 (es) Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187)
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
BR112016023926A2 (pt) heterociclil sulfonas substituídas por aril
ECSP22003596A (es) Moduladores del receptor de nmda